Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer

Biomarkers

Volumn 19, Issue 1, 2014, Pages 34-42

  Sang, Meixiang ^a,b   Wu, Xiaohua ^a   Fan, Xiaojie ^b   Sang, Meijie ^b,c   Zhou, Xinliang ^b   Zhou, Nan ^a  

^a BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Circulating tumor cells; MAGE; Ovarian cancer; Surveillance marker

Indexed keywords

BIOLOGICAL MARKER; MELANOMA ANTIGEN; MELANOMA ASSOCIATED ANTIGEN A; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAGE A GENE; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; STATISTICAL ANALYSIS;

CA-125 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MELANOMA-SPECIFIC ANTIGENS; MULTIVARIATE ANALYSIS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS;

EID: 84893296472     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.865275     Document Type: Article

References (31)

1. Balic M, Lin H, Williams A, et al. (2012). Progress in circulating tumor cell capture and analysis: Implications for cancer management. Expert Rev Mol Diagn 12:303-12.
2. Bednarz-Knoll N, Alix-Panabières C, Pantel K. (2011). Clinical relevance and biology of circulating t umor cells. Breast Cancer Res 13:228-38.
3. Bergeron A, Picard V, LaRue H, et al. (2009). High frequency of MAGEA4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 125:1365-71.
4. Brasseur F, Rimoldi D, Liénard D, et al. (1995). Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63: 375-80.
5. Braun S, Schindlbeck C, Hepp F, et al. (2001). Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol 19: 368-75.
6. Bukowski RM, Ozols RF, Markman M. (2007). The management of recurrent ovarian cancer. Semin Oncol 34:S1-15.
7. Cain JM, Ellis GK, Collins C, et al. (1990). Bone marrow involvement in epitheli al ovarian cancer by immunocytochemical assessment. Gynecol Oncol 38:442-5.
8. De Plaen E, Arden K, Traversari C, et al. (1994). Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360-9.
9. Gillespie AM, Rodgers S, Wilson AP, et al. (1998). MAGE, BAGE and GAGE: Tumor antigen expression in benign and malignant ovarian tissue. Br J Cancer 78:816-21.
10. Jacobs I, Bast Jr RC. (1989). The CA 125 tumour-associated antigen: A review of the literature. Hum Reprod 4:1-12.
11. Jacobs IJ, Menon U. (2004). Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3:355-66.
12. Jemal A, Murray T, Samuels A, et al. (2003). Cancer statistics. CA Cancer J Clin 53:5-26.
13. Judson PL, Geller MA, Bliss RL, et al. (2003). Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol 91:389-94.
14. Kwon S , Kang SH, Ro J, et al. (2005). The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma. Cancer 104:251-6.
15. Lian Y, Sang M, Ding C, et al. (2012). Expressions of MAGEA10 and MAGE-A11 in breast cancers and their prognostic significance: A retrospective clinical study. J Cancer Res Clin Oncol 138:519-27.
16. Marth C, Kisic J, Kaern J, et al. (2002). Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer 94:707-12.
17. Miyashiro I, Kuo C, Huynh K, et al. (2001). Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem 47:505-12.
18. Otte M, Zafrakas M, Riethdorf L, et al. (2001). MAGE-A gene expression pattern in primary breast cancer. Cancer Res 61: 6682-7.
19. Rogner UC, Wilke K, Steck E, et al. (1995). The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Geno mics 29:725-31.
20. Russo V, Dalerba P, Ricci A, et al. (1996). MAGE, BAGE, and GAGE genes expression in fresh epithelial ovarian carcinomas. Int J Cancer 67:457-60.
21. Sang M, Lian Y, Zhou X, Shan B. (2011a). MAGE-A family: Attractive targets for cancer immunotherapy. Vaccine 29:8496-500.
22. Sang M, Wang L, Ding C, et al. (2011b). Melanoma-associated antigen genes-an update. Cancer Lett 302:85-90.
23. Swaby RF, Cristofanilli M. (2011). Circulating tumor cells in breast cancer: A tool whose time has come of age. BMC Med 9:43. doi: 10.1186/174 1-7015-9-43.
24. Van Der Bruggen P, Traversari C, Chomez P, et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-7.
25. Van De St olpe A, Pantel K, Sleijfer S, et al. (2011). Circulating tumor cell isolation and diagnostics: Toward routine clinical use. Cancer Res 71: 5955-60.
26. Weiland F, Martin K, Oehler MK, Hoffmann P. (2 012). Deciphering the molecular nature of ovarian cancer biomarker CA125. Int J Mol Sci 13:10568-82.
27. Yakirevich E, Sabo E, Lavie O, et al. (2003). Expression of the MAGEA4 and NY-ESO-1 cancer-testi s antigens in serous ovarian neoplasms. Clin Cancer Res 9:6453-60.
28. Yamada A, Kataoka A, Shichijo S, et al. (2005). Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. I nt J Cancer 64:388-93.
29. Yap TA, Carden CP, Kaye SB. (2009). Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer 9:167-81.
30. Zhang S, Zhou X, Yu H, Yu Y. (2010). Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 10:163. doi: 10.1186/1471-2407-10-163.
31. Zimmermann AK, Imig J, Klar A, et al. (2013). Expression of MAGEC1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. Virchows Arch 462:565-74.